CN118660907A - 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法 - Google Patents

用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法 Download PDF

Info

Publication number
CN118660907A
CN118660907A CN202280078694.3A CN202280078694A CN118660907A CN 118660907 A CN118660907 A CN 118660907A CN 202280078694 A CN202280078694 A CN 202280078694A CN 118660907 A CN118660907 A CN 118660907A
Authority
CN
China
Prior art keywords
specifically binds
chain variable
variable region
hiv proteins
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280078694.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·R·魏
L·徐
Z-Y·杨
G·J·纳贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modes Medical Co ltd
Original Assignee
Modes Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modes Medical Co ltd filed Critical Modes Medical Co ltd
Publication of CN118660907A publication Critical patent/CN118660907A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280078694.3A 2021-09-29 2022-09-28 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法 Pending CN118660907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29
US63/249,722 2021-09-29
PCT/US2022/077203 WO2023056315A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv

Publications (1)

Publication Number Publication Date
CN118660907A true CN118660907A (zh) 2024-09-17

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280078694.3A Pending CN118660907A (zh) 2021-09-29 2022-09-28 用于hiv的抗原结合多肽、抗原结合多肽复合物及其使用方法

Country Status (13)

Country Link
US (1) US20250197481A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408892A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537827A (cg-RX-API-DMAC7.html)
KR (1) KR20240099226A9 (cg-RX-API-DMAC7.html)
CN (1) CN118660907A (cg-RX-API-DMAC7.html)
AR (1) AR127176A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022357501A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232365A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000890A1 (cg-RX-API-DMAC7.html)
IL (1) IL311762A (cg-RX-API-DMAC7.html)
MX (1) MX2024003804A (cg-RX-API-DMAC7.html)
TW (1) TW202325744A (cg-RX-API-DMAC7.html)
WO (1) WO2023056315A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6407726B2 (ja) * 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Also Published As

Publication number Publication date
WO2023056315A1 (en) 2023-04-06
EP4408892A4 (en) 2025-11-19
US20250197481A1 (en) 2025-06-19
EP4408892A1 (en) 2024-08-07
JP2024537827A (ja) 2024-10-16
KR20240099226A9 (ko) 2025-12-10
MX2024003804A (es) 2024-06-11
CL2024000890A1 (es) 2024-10-11
TW202325744A (zh) 2023-07-01
IL311762A (en) 2024-05-01
CA3232365A1 (en) 2023-04-06
AR127176A1 (es) 2023-12-27
KR20240099226A (ko) 2024-06-28
AU2022357501A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
EP3365366B1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
AU2015295936B2 (en) Anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
US20230235092A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
CN110072891A (zh) 抗人cd73抗体
AU2018346264B2 (en) Cysteine engineered antigen-binding molecules
US20240059798A1 (en) Conditionally activated antigen binding polypeptide complexes and methods of use thereof
KR20230136166A (ko) 멀타바디 구축물, 조성물, 및 방법
US20240034808A1 (en) Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligands
WO2023186081A1 (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
IL317895A (en) Anti-SARS-COV-2 antigen-binding polypeptides, polypeptide complexes and methods of using them
JP2023547662A (ja) Cldn6及びcd3に選択的に結合するポリペプチド構築物
EP4547711A2 (en) Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
CN117597365A (zh) 多特异性fgf21受体激动剂及其应用
WO2026072755A2 (en) Single-chain fab proteins and uses thereof
CN118019767A (zh) 优化的multabody构建体、组合物和方法
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination